Kelun-Biotech Advances 30+ Oncology Candidates as ADC Pipeline Race Accelerates Through 2027
Chinese biotech Kelun-Biotech is advancing 30+ oncology candidates including novel antibody-drug conjugates (ADCs) as major pharmaceutical companies push targeted therapies through late-stage trials. Regulatory milestones concentrated in 2026-2027 signal an intense approval cycle for cancer treatments, with established players Pfizer, Regeneron, and BioNTech competing across multiple cancer types.
Salvado•